Anzeige
Meldung des Tages: 20-Milliarden-Markt vor dem Durchbruch: Dieser Drohnen-Player baut ein komplettes Luftfahrt-Ökosystem auf

Ideaya Bioscience News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
35,06 $
+1,89 $
+5,70%
30,156 € 09.03.26
Depot/Watchlist
Marktkapitalisierung *
2,62 Mrd. €
Streubesitz
-
KGV
-28,46
Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

09.03.26 - PR Newswire
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
IDEAYA Biosciences Announces First-​Patient-In for Phase 1 Trial of IDE892, a Potential Best-​In-Class PRMT5 Inhibitor for MTAP-​Deleted Solid Tumors, and Provides MTAP and ...
27.02.26 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
25.02.26 - PR Newswire
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
IDEAYA Biosciences Announces First-​Patient-In for Phase 1 Trial of IDE034, a Potential First-​In-Class B7H3/PTK7 Bispecific TOP1 ADC PR Newswire
23.02.26 - PR Newswire
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer PR Newswire
17.02.26 - PR Newswire
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update PR Newswire
02.02.26 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events PR Newswire
30.01.26 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11.01.26 - PR Newswire
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
05.01.26 - PR Newswire
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
11.12.25 - PR Newswire
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-​line HLA*A2-...
10.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-​In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers PR Newswire
01.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-​in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire
28.11.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.11.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events PR Newswire
04.11.25 - PR Newswire
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
31.10.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.10.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire
20.10.25 - PR Newswire
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 ...
20.10.25 - PR Newswire
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-​line Metastatic Uveal Melanoma at the ...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire

Newssuche

Videos

newspaper
04.03.26 -6,24%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »